Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Cutler, Corey

doi:10.1182/asheducation-2014.1.77

Cited by 9 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) not only improves survival times in patients with acute myeloid leukemia [1] and acute lymphoid leukemia [2], but may also be the only curative therapy for very severe aplastic anemia [3]. Nonetheless, the morbidity and mortality that are associated with allo-HSCT limit its clinical application and efficacy.…”

Section: Introductionmentioning

confidence: 99%

Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area

Lin¹,

Han²,

Hwang³

et al. 2017

Tjh

View full text Add to dashboard Cite

Objective:Although Cytomegalovirus (CMV) infection is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), the risk factors for CMV reactivation and treatment failure in CMV endemic areas have remained unclear. This study investigated the risk factors for CMV reactivation among allo-HSCT recipients in an area where CMV is highly endemic.Materials and Methods:Medical records of 82 allo-HSCT recipients from a CMV endemic area were retrospectively reviewed. The patients were stratified into two groups: those with CMV reactivation (n=32) and those without CMV reactivation (n=50). We investigated possible variables associated with CMV reactivation and treatment failure.Results:Univariate analyses showed that non-remission disease status [hazard ratio (HR): 2.15; p=0.032] and ≥grade III acute graft-versus-host disease (GVHD) (HR: 3.07; p=0.002) were associated with CMV reactivation. Multivariate analysis further demonstrated that older age (HR: 1.03; p=0.029) and ≥grade III acute GVHD (HR: 2.98; p=0.012) were associated with CMV reactivation. Overall survival time seemed lower among patients with CMV reactivation than among patients without CMV reactivation, although the difference was not statistically significant (p=0.165). The absence of ≥grade III acute GVHD was associated with successful CMV treatment in the current study (odds ratio: 4.40; p=0.008).Conclusion:Prophylactic anti-CMV therapy might need to be considered for allo-HSCT recipients who have ≥grade III GVHD.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area

Lin¹,

Han²,

Hwang³

et al. 2017

Tjh

View full text Add to dashboard Cite

show abstract

“…Mimo wielu analiz retrospektywnych pytanie o optymalne leczenie cytoredukujące przed planowanym allo-HSCT pozostaje nierozstrzygnięte. Standardowym postępowaniem pozostaje konwencjonalna chemioterapia, ale wiele danych przemawia za podobną skutecznością (przy niższej toksyczności) terapii hipometylujacej [40][41][42][43]; być może, problem ten pozwolą rozwiązać wyniki randomizowanego badania służącego porównaniu AZA z konwencjonalną chemioterapią indukującą (NCT01812252).…”

Section: Leczenieunclassified

Nowotwory mieloproliferacyjne i zespoły mielodysplastyczne — postępy w diagnostyce i terapii

Góra‐Tybor¹

2015

Hematologia

View full text Add to dashboard Cite

W ostatnich latach dokonał się bardzo duży postęp w zakresie diagnostyki i terapii nowotworów mieloproliferacyjnych i zespołów mielodysplastycznych. Dostępność nowych technik sekwencjonowania pozwoliła na zidentyfikowanie licznych mutacji somatycznych składających się na złożony obraz molekularny tej grupy nowotworów. Poznanie mechanizmów patogenetycznych zaowocowało z kolei rozwojem skutecznych terapii celowanych. Jednocześnie są konstruowane nowe skale prognostyczne, które pozwalają na właściwą kwalifikację pacjentów do odpowiedniego rodzaju terapii.

show abstract

“…Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is an essential treatment for various haematological diseases. Allo‐HSCT not only increases the overall survival time in patients with acute myeloid leukaemia (AML) (Chang et al, 2016) but also may be the only curative therapy for some non‐malignant haematological diseases (Cutler, 2014). However, multiple infusions of chemotherapeutic agents, blood transfusion, parental nutrition and blood sampling are unavoidable during this treatment.…”

Section: Introductionmentioning

confidence: 99%

Dual‐lumen power injectable peripherally inserted central catheters in allogeneic hematopoietic stem cell transplantation: A prospective observational study

Shih

Teng

Chen

et al. 2021

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aims and Objectives To explore whether dual‐lumen power injectable peripherally inserted central catheters (PICCs) could be effectively and safely applied in allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and for serum cyclosporine level monitoring. Background Compared to conventional central venous access devices, PICC provides a feasible route not only for fluid infusion, but also for blood sample collection in patients undergoing oncological treatments. Design A prospective observational study was conducted according to the STROBE guidelines. Methods We prospectively evaluated the applications and complications of power injectable PICCs in 52 consecutive allo‐HSCT recipients. We also compared the cyclosporine levels in 188 paired blood samples, simultaneously obtained via power injectable PICCs and percutaneous venous puncture, to investigate whether power injectable PICC is a feasible route for cyclosporine concentration monitoring in allo‐HSCT. Results The median PICC placement duration was 29 days. The insertion‐site blood oozing and central line‐associated bloodstream infection rates were 36.5% (19/52) and 26.9% (14/52), respectively, indicating the feasibility of these PICCs for various applications in allo‐HSCT. No power injectable PICC‐related thrombotic adverse events were identified; 90.4% (47/52) of cases with power injectable PICC removal occurred because of lack of medical utility, suggesting that power injectable PICC‐related complications were manageable. However, cyclosporine levels in samples obtained via these PICCs were significantly higher than those in samples obtained via percutaneous venous puncture (261.5 ± 139.2 vs. 232.4 ± 253.6 ng/ml; p = 0.019 [set 1]; 254.8 ± 89.3 vs. 225.1 ± 233.3 ng/ml; p<0.001 [set 2]; 283.6 ± 103.9 vs. 238.0 ± 254.7 ng/ml; p = 0.006 [set 3]; 291.0 ± 94.9 vs. 266.0 ± 274.7 ng/ml; p = 0.016 [set 4]). Conclusion The power injectable PICC is a feasible venous access device for allo‐HSCT. Relevance to clinical practice The dual‐lumen power injectable PICCs provided a reliable access for blood sample collection, decreasing the number of blind percutaneous venous punctures in allo‐HSCT. However, its application in cyclosporine level monitoring needs further investigation.

show abstract

Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia

Cited by 9 publications

References 25 publications

Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area

Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area

Nowotwory mieloproliferacyjne i zespoły mielodysplastyczne — postępy w diagnostyce i terapii

Dual‐lumen power injectable peripherally inserted central catheters in allogeneic hematopoietic stem cell transplantation: A prospective observational study

Contact Info

Product

Resources

About